European Commission approves Gilead’s HCV triple combo

Gilead Sciences Inc. (NASDAQ:GILD) said the European Commission approved Vosevi sofosbuvir/velpatasvir/voxilaprevir to treat HCV genotypes 1-6 infection in adults.

The drug is approved as a 12-week regimen for patients without cirrhosis or with compensated cirrhosis who previously failed a direct-acting antiviral (DAA)-containing regimen. The EC also approved a 12-week regimen for use in DAA-naïve patients with compensated cirrhosis with an option to shorten therapy to 8 weeks for those infected with genotype 3...